FDA · Drug approval ·
FDA approval of MEKTOVI for certain cancers
The FDA has approved MEKTOVI (binimetinib) to be used with encorafenib for specific melanoma and lung cancer with BRAF mutations.
The US Food and Drug Administration has approved MEKTOVI (binimetinib), an oral kinase inhibitor, to be used in combination with encorafenib. A kinase inhibitor is a medicine that targets certain signaling proteins in cancer cells.
MEKTOVI is for treatment of patients with unresectable or metastatic melanoma that has a BRAF V600E or V600K mutation, and for adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation. These mutations must be detected by an FDA-approved test.
This matters because the approval is for people whose tumors have these specific BRAF mutations. If your cancer test shows a listed mutation, MEKTOVI may be an option to discuss with your care team.